Randomized, double ‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

Cancer Medicine, EarlyView.

Source: Cancer Medicine - August 20, 2018 Category: Cancer & Oncology Authors: David Fogelman , Antonio Cubillo , Pilar Garc ía‐Alfonso , María Luisa Limón Mirón , John Nemunaitis , Daniel Flora , Christophe Borg , Laurent Mineur , Jose M. Vieitez , Allen Cohn , Gene Saylors , Alber Source Type: research